The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1223
Ziconotide (Prialt) for Chronic Pain
The full article is available to subscribers Subscriber Login   

The FDA has approved ziconotide (Prialt – Elan) intrathecal infusion for management of severe chronic pain in patients who are intolerant of or refractory to other treatments. Ziconotide is a synthetic neuronal N-type calcium channel blocker. It is intended for use with a programmable implanted microinfusion device, but an external microinfusion device can be used temporarily.

INTRATHECAL TREATMENT OF PAIN — Intraspinal (intrathecal or epidural) administration of analgesics is usually tried only when standard treatments have failed.1 Morphine (Infumorph, Astramorph) is approved for treatment of chronic pain by intrathecal administration. Baclofen (Lioresal) is approved for intrathecal treatment of spasticity. Other opioids, ketamine (Ketalar, and others), midazolam (Versed, and others), clonidine and local anesthetics such as lidocaine and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Ziconotide (Prialt) for Chronic Pain
Article code: 1223d
 Electronic, downloadable article - $25